Inclusion Criteria:

Participants must meet all of the following criteria:

- Male or Female patients 18 years and older.

- Patient with a diagnosis of chronic myelogenous leukemia in chronic phase

- Within 6 months of initial diagnosis.

- Received any treatment for CML for less than 1 month prior to study entry with the
exception of hydroxyurea and/or anagrelide.

Exclusion Criteria:

- Late chronic phase, accelerated phase or blastic phase

- Taking any other investigational agents within 28 days of starting the study

- If sibling donors have been identified and where allogeneic bone marrow
transplantation will be the first line treatment.

- Another primary malignancy /cancer unless it is not considered clinically significant
or does not require active intervention.

- If patients have heart problems or complications

- Pregnant or breast-feeding females

- Severe and/or uncontrolled disease such as diabetes, chronic renal disease, etc.

- Chronic liver disease (i.e., chronic active hepatitis, and cirrhosis).

- Diagnosis of human immunodeficiency virus (HIV) infection.

- Received any treatment for CML for longer than 1 month prior to study entry with the
exception of hydroxyurea and/or anagrelide.

- Patient previously received radiotherapy to greater than 25% of the bone marrow.

- Patient had a major surgery within 4 weeks prior to study entry